Dr. Goy Discusses Single-Agent Ibrutinib in MCL

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses single-agent ibrutinib (Imbruvica) in mantle cell lymphoma (MCL).

A long-term follow-up of single-agent ibrutinib was presented at the 2017 ASH Annual Meeting. Goy reports that the complete response rate was up to 26%. Additionally, at 3 years, one-quarter of patients still had not progressed.

However, work still needs to be done to determine which patients would benefit best from ibrutinib, Goy adds.